Fimasartan is an angiotensin II receptor antagonist (ARB) used to treat hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.
- Mechanism
- Curator reviewed · 3 references
Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at α1-adrenergic receptors. It also stimulates secretion of aldosterone which acts to increase sodium and water reabsorption in the renal tubules. Fimasartan bind to and antagonizes AR1 preventing vasoconstriction and reducing aldosterone secretion to increase natriuresis leading to a reduction in blood volume. Together these effects produce an anti-hypertensive effect.
- Primary indication
- Used for the treatment of hypertension and heart failure.Curator reviewed · 1 structured indication
- Formula / weight
- C27H31N7OS · 501.65 g/mol (avg)
- Code names
- BR1015-1 · BR1015-3
Resolves to
AMEROGPZOLAFBN-UHFFFAOYSA-NSMILESCCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1What you can answer from here — as of September 14, 2026
Which drugs share a target with Fimasartan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account